New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies | Zendy

Laetitia Devy | Zendy; Daniel T. Dransfield | Zendy

Open Access

New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies

Author(s) -

Laetitia Devy,

Daniel T. Dransfield

Publication year - 2010

Publication title -

biochemistry research international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.631

H-Index - 36

eISSN - 2090-2255

pISSN - 2090-2247

DOI - 10.1155/2011/191670

Subject(s) - matrix metalloproteinase , proteases , medicine , inflammation , metalloproteinase , antibody , matrix metalloproteinase inhibitor , bioinformatics , cancer research , immunology , enzyme , biology , biochemistry

MMP intervention strategies have met with limited clinical success due to severe toxicities. In particular, treatment with broad-spectrum MMP-inhibitors (MMPIs) caused musculoskeletal pain and inflammation. Selectivity may be essential for realizing the clinical potential of MMPIs. Here we review discoveries pinpointing membrane-bound MMPs as mediators of mechanisms underlying cancer and inflammation and as possible therapeutic targets for prevention/treatment of these diseases. We discuss strategies to target these therapeutic proteases using highly selective inhibitory agents (i.e., human blocking antibodies) against individual membrane-bound MMPs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research